| The Results of a Combination of Cataract Surgery and Intravitreal Bevacizumab Injection for Diabetic Macular Edema. |
|
Bu Ki Kim, Eui Yong Kweon, Dong Wook Lee, Min Ahn, Nam Chun Cho |
|
Department of Ophthalmology, Chonbuk National University Medical School, Jeonju, Korea. key@chonbuk.ac.kr |
| 당뇨황반부종 환자에서 백내장적출술과 유리체내 베바시주맙주입술 동시 수술의 효과 |
|
김부기ㆍ권의용ㆍ이동욱ㆍ안민ㆍ조남천 |
|
Department of Ophthalmology, Chonbuk National University Medical School, Jeonju, Korea |
|
|
| Abstract |
PURPOSE
To evaluate the efficacy and safety of the combination of cataract surgery and intravitreal bevacizumab injection in patients with cataract and diabetic macular edema. METHODS: Patients received an intravitreal injection of bevacizumab(1.25 mg) combined with phacoemulsification and implantation of a posterior chamber intraocular lens. Best corrected visual acuity (BCVA, LogMAR) and, central macular thickness (CMT) were measured using OCT at baseline and at one week, one, three, and six months after surgery, and adverse events were recorded. RESULTS: The mean baseline LogMAR BCVA was 0.84+/-0.50 and mean CMT was 337.1+/-57.50 micrometer. At one week, one, three, and six months after surgery, the mean BCVAs were 0.52+/-0.40, 0.51+/-0.42, 0.52+/-0.34, and 0.46+/-0.37, and the mean CMTs were 356.4+/-86.44 micrometer, 338.8+/-138.4 micrometer, 349.0+/-122.9 micrometer, and 334.2+/-100.4 micrometer, respectively. No adverse events associated with cataract surgery or intravitreal bevacizumab injection were observed. CONCLUSIONS: The short-term results from the present study suggest the combination of cataract surgery and intravitreal bevacizumab injection are safe and effective for the prevention of macular edema aggravation for one month, but has little effect on prevention of macular edema aggravation three months after surgery for diabetic macular edema patients. |
| Key Words:
Bevacizumab;Cataract surgery;Diabetic macular edema |
|
PDF Links
Full text via DOI
Download Citation
